Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Drugs
Gillian M Keating

Abstract

Azacitidine (Vidaza®) is a pyrimidine nucleoside analogue of cytidine. This article reviews the clinical efficacy and tolerability of azacitidine in the treatment of patients with myelodysplastic syndromes (MDS)/acute myeloid leukaemia (AML), as well as summarizing its pharmacological properties. The randomized, multicentre Cancer and Leukemia Group B 9221 trial compared the efficacy of subcutaneous azacitidine with that of supportive care alone in patients with MDS fulfilling French-American-British (FAB) classification criteria. The overall response rate, the complete response rate and the complete plus partial response rate were significantly higher in patients receiving azacitidine than in those receiving supportive care alone. The randomized, open-label, multicentre AZA-001 trial compared the efficacy of subcutaneous azacitidine with that of conventional care in adults with higher-risk (i.e. International Prognostic Scoring System intermediate-2-risk or high-risk classification) MDS/AML. Prior to randomization, investigators preselected patients to the conventional care strategy considered most appropriate (i.e. best supportive care, low-dose cytarabine or intensive chemotherapy). The median duration of overall survival wa...Continue Reading

References

Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
Apr 3, 2001·Annals of Internal Medicine·V SantiniJ P Issa
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice B KornblithJimmie C Holland
Apr 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michelle A RudekSharyn D Baker
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanUNKNOWN Cancer and Leukemia Group B
Nov 29, 2007·Expert Opinion on Investigational Drugs·Haifaa Abdulhaq, James M Rossetti
Jan 22, 2008·Experimental Hematology·Rasheed KhanEva Hellström-Lindberg
May 10, 2008·Blood·Stephen D Nimer
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Jan 15, 2009·Journal of Internal Medicine·M Jädersten, E Hellström-Lindberg
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger M LyonsC L Beach
Apr 23, 2009·Blood·Richard M Stone
Jun 23, 2009·Bone Marrow Transplantation·T FieldC Anasetti
Jul 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria Teresa VosoGiuseppe Leone
Aug 4, 2009·American Journal of Hematology·Mike G MartinRavi Vij
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Matilde Y FolloLucio Cocco
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Jan 13, 2010·British Journal of Haematology·Bart L ScottH Joachim Deeg
Feb 2, 2010·Cancer Chemotherapy and Pharmacology·Yong ChenSekhar Surapaneni
Feb 13, 2010·Cancer·Pellegrino MustoUNKNOWN Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias
Apr 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mikkael A SekeresJaroslaw P Maciejewski
Jun 1, 2010·Clinical Lymphoma, Myeloma & Leukemia·G Nicolas BattyFarhad Ravandi
Sep 24, 2010·Epigenetics : Official Journal of the DNA Methylation Society·Ilan BernsteinAllen S Yang

❮ Previous
Next ❯

Citations

Jul 22, 2014·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Fabiana S GomesEliana P Araújo
Sep 17, 2014·Leukemia & Lymphoma·Ken WatanabeKazuteru Ohashi
Dec 17, 2014·Expert Opinion on Drug Metabolism & Toxicology·Cindy SerdjebiJoseph Ciccolini
Dec 4, 2012·Best Practice & Research. Clinical Haematology·David P Steensma
May 7, 2014·European Journal of Haematology·Shiue-Wei LaiYi-Ying Wu
Jul 6, 2014·Blood·Leonie I KroezeUNKNOWN EORTC Leukemia Group and GIMEMA
Aug 21, 2014·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Marco MiceliLucia Altucci
Oct 30, 2012·Molecular Oncology·Angela NebbiosoLucia Altucci
Feb 6, 2017·Journal of Hematology & Oncology·Yan LiLi Yu
Feb 17, 2017·Therapeutic Advances in Hematology·George YaghmourMike G Martin
Sep 3, 2013·Clinical Medicine Insights. Oncology·Fuad El Rassi, Martha Arellano
Feb 13, 2018·BMC Hematology·Roman M Shapiro, Alejandro Lazo-Langner
Oct 17, 2014·EMBO Molecular Medicine·Madhuri BhuvanagiriAndreas E Kulozik
May 24, 2014·The Journal of Biological Chemistry·Steve PoirierGaétan Mayer
Oct 1, 2012·Acta Neuropsychiatrica·Andreas Lennartsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.